Precision Oncology in AML: Molecular Insights, Maintenance Strategies, and Emerging Therapies

home / face-off / precision-oncology-in-aml-molecular-insights-maintenance-strategies-and-emerging-therapies

Panelists discuss how emerging therapies like CC-486, venetoclax, and menin inhibitors are reshaping treatment strategies for relapsed and refractory acute myeloid leukemia while debating the role of posttransplant maintenance and personalized approaches based on genetic mutations such as NPM1 and TP53.

All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

EP. 1: All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

December 23rd 2024

Panelists discuss how the all-oral regimen of oral azacitidine and venetoclax offers a promising treatment option for newly diagnosed and relapsed/refractory acute myeloid leukemia, highlighting its potential to improve patient outcomes and simplify treatment administration.

AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

EP. 2: AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

January 3rd 2025

Panelists discuss how the updated results and longer follow-up from the AUGMENT-101 study of revumenib demonstrate its potential to improve outcomes in patients with relapsed/refractory KMT2Ar acute leukemia, offering a promising new option in this challenging subset of acute myeloid leukemia.

Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

EP. 3: Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

January 9th 2025

Panelists debate the best posttransplant follow-up approach for acute myeloid leukemia, weighing the benefits of maintenance therapy vs close monitoring with regular laboratory testing to optimize patient outcomes and minimize long-term risks.

Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

EP. 4: Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

January 16th 2025

Panelists debate the treatment of relapsed/recurrent acute myeloid leukemia, comparing the potential of menin inhibitors to standard-of-care therapies, including chemotherapy and BCL2 inhibitors, in improving patient outcomes.